구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Bimzelx (bimekizumab) | Secikinumab | Ixekizumab | AIN457 (secukinumab) |
Overview Company | UCB | Novartis Pharmaceuticals | Eli Lilly and Company | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | Psoriasis | Psoriatic Arthritis | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Axial Spondylarthritis (axSpA); Secukinumab | Psoriasis; Atopic Dermatitis | Asthma |
Overview Phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Limited Data | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Watch | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | — |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — | — | — |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — | — | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | — | targets and signaling pathway | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | — | — | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~23 days | — | 13 h | 31 h |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | — | Mouse | Rat, Human |
PK/PD Animal (cat.) | Human, NHP, In vitro | — | Mouse | Human, Rat |
PK/PD Experiment | pd | — | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey | — | Mouse | Rat, Human |
Toxicology Animal (cat.) | — | — | Mouse | Human, Rat |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | — | — | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | — | — | 9% |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai | — | — | — |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | — | — | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — | — | No active/completed counts |
Clinical Trial ref | NCT03536884 | — | — | NCT03131570 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Bimzelx (bimekizumab) | Secikinumab | Ixekizumab | AIN457 (secukinumab) |
Overview Company | UCB | Novartis Pharmaceuticals | Eli Lilly and Company | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A / IL-17F | Psoriasis | Psoriatic Arthritis | Psoriatic Arthritis |
Overview Indication | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Axial Spondylarthritis (axSpA); Secukinumab | Psoriasis; Atopic Dermatitis | Asthma |
Overview Phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Limited Data | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Low | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Watch | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | — |
Positioning Known limitation | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — | — | — |
Positioning Development positioning | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — | — | — |
MoA Mechanism | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | — | targets and signaling pathway | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI/IGA response, hs-CRP in axial disease. | — | — | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~23 days | — | 13 h | 31 h |
PK/PD Species | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | — | Mouse | Rat, Human |
PK/PD Animal (cat.) | Human, NHP, In vitro | — | Mouse | Human, Rat |
PK/PD Experiment | pd | — | pharmacokinetic | PD |
Toxicology Species | Cynomolgus monkey | — | Mouse | Rat, Human |
Toxicology Animal (cat.) | — | — | Mouse | Human, Rat |
Toxicology Major finding | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | — | — | — |
Clinical Safety signal | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | — | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | — | — | 9% |
Clinical PASI75 | PASI 100 than secukinumab at week 16 and mai | — | — | — |
Clinical Result source | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | — | — | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | PRECLINICAL | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — | — | No active/completed counts |
Clinical Trial ref | NCT03536884 | — | — | NCT03131570 |
추천 비교
추천 비교